{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:11:19Z","timestamp":1774260679592,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T00:00:00Z","timestamp":1680393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["CRSII5_180323"],"award-info":[{"award-number":["CRSII5_180323"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jconrel.2023.03.059","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T14:00:22Z","timestamp":1680703222000},"page":"264-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Development of an inhalable antiviral powder formulation against respiratory syncytial virus"],"prefix":"10.1016","volume":"357","author":[{"given":"Rick","family":"Heida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Akkerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo H.","family":"Jacob Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke J.","family":"Lakerveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Bigogno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Gasbarri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puck B.","family":"van Kasteren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Stellacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henderik W.","family":"Frijlink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke L.W.","family":"Huckriede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter L.J.","family":"Hinrichs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.03.059_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.631736","article-title":"Pandemics throughout history","volume":"11","author":"Piret","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100986","article-title":"Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019","volume":"37","author":"Jin","year":"2021","journal-title":"EClinicalMedicine."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0015","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/S1473-3099(22)00510-2","article-title":"Age\u2013sex differences in the global burden of lower respiratory infections and risk factors, 1990\u20132019: results from the Global Burden of Disease Study 2019","volume":"22","author":"Kyu","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0020","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2023.03.059_bb0025","article-title":"The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study","volume":"0","author":"Wildenbeest","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/ciy991","article-title":"Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults","volume":"69","author":"Ackerson","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0035","series-title":"What is RSV and why is it surging across the U.S.?","author":"Johnson","year":"2022"},{"key":"10.1016\/j.jconrel.2023.03.059_bb0040","article-title":"Preparing for uncertainty: endemic paediatric viral illnesses after COVID-19 pandemic disruption","volume":"0","author":"Messacar","year":"2022","journal-title":"Lancet."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0050","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1093\/cid\/ciz835","article-title":"Respiratory syncytial virus infection morbidity in the elderly: time for repurposing of ribavirin?","volume":"70","author":"de Zwart","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0055","first-page":"35","article-title":"Expert consensus on palivizumab use for respiratory syncytial virus in developed countries","volume":"33","author":"Luna","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0060","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0065","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/14760584.2019.1657013","article-title":"Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly","volume":"18","author":"Beugeling","year":"2019","journal-title":"Expert Rev. Vaccines."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.healun.2008.10.008","article-title":"Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection","volume":"28","author":"Pelaez","year":"2009","journal-title":"J. Hear. Lung Transplant."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0075","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2020.10.009","article-title":"Advances in the development of entry inhibitors for sialic-acid-targeting viruses","volume":"26","author":"Heida","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2023.03.059_bb0080","doi-asserted-by":"crossref","first-page":"2001012","DOI":"10.1002\/advs.202001012","article-title":"Non-toxic virucidal macromolecules show high efficacy against influenza virus ex vivo and in vivo","volume":"8","author":"Kocabiyik","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0085","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nmat5053","article-title":"Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism","volume":"17","author":"Cagno","year":"2018","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0090","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3390\/v11070596","article-title":"Heparan sulfate proteoglycans and viral attachment: true receptors or adaptation Bias?","volume":"11","author":"Cagno","year":"2019","journal-title":"Viruses."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax9318","article-title":"Modified cyclodextrins as broad-spectrum antivirals","volume":"6","author":"Jones","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02001-20","article-title":"Sulfonated nanomaterials with broad-spectrum antiviral activity extending beyond heparan sulfate-dependent viruses","volume":"64","author":"Cagno","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0105","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1128\/JVI.76.11.5654-5666.2002","article-title":"Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology","volume":"76","author":"Zhang","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0110","doi-asserted-by":"crossref","first-page":"L833","DOI":"10.1152\/ajplung.00173.2001","article-title":"Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia","volume":"282","author":"Southam","year":"2002","journal-title":"Am. J. Physiol. Cell. Mol. Physiol."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/pharmaceutics12010024","article-title":"Dispersibility and storage stability optimization of high dose isoniazid dry powder inhalation formulations with L-leucine or trileucine","volume":"12","author":"Sibum","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0120","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jconrel.2021.06.045","article-title":"Trileucine as a dispersibility enhancer of spray-dried inhalable microparticles","volume":"336","author":"Ordoubadi","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.03.059_bb0125","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jps.21078","article-title":"Trileucine improves aerosol performance and stability of spray-dried powders for inhalation","volume":"97","author":"Lechuga-Ballesteros","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0130","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/pharmaceutics12070645","article-title":"Automated filling equipment allows increase in the maximum dose to be filled in the Cyclops\u00ae high dose dry powder inhalation device while maintaining dispersibility","volume":"12","author":"Sibum","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejpb.2015.01.012","article-title":"The Cyclops for pulmonary delivery of aminoglycosides; a new member of the TwincerTM family","volume":"90","author":"Hoppentocht","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0140","series-title":"Eur. Pharmacopoeia","first-page":"331","article-title":"Preparations for inhalation: aerodynamic assessment of fine particles","author":"Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM)","year":"2016"},{"key":"10.1016\/j.jconrel.2023.03.059_bb0145","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijpharm.2012.08.020","article-title":"Characterisation of high dose aerosols from dry powder inhalers","volume":"437","author":"Grasmeijer","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0150","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/i560156a015","article-title":"Qualitative test for carbohydrate material","volume":"18","author":"Dreywood","year":"1946","journal-title":"Ind. Eng. Chem. Anal. Ed."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejpb.2015.10.003","article-title":"A levodopa dry powder inhaler for the treatment of Parkinson\u2019s disease patients in off periods","volume":"97","author":"Luinstra","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0160","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1743-422X-9-253","article-title":"An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting","volume":"9","author":"van Remmerden","year":"2012","journal-title":"Virol. J."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0165","series-title":"Virol. Methods Man","first-page":"25","article-title":"Virus isolation and quantitation","author":"Hierholzer","year":"1996"},{"key":"10.1016\/j.jconrel.2023.03.059_bb0170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.addr.2014.04.004","article-title":"Technological and practical challenges of dry powder inhalers and formulations","volume":"75","author":"Hoppentocht","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.cocis.2021.101497","article-title":"Natural and bioinspired excipients for dry powder inhalation formulations","volume":"56","author":"Zillen","year":"2021","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121590","article-title":"Effect of pressure drop on the in vitro dispersion of adhesive mixtures of different blend states for inhalation","volume":"617","author":"Rud\u00e9n","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0185","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/JCM.43.5.2356-2362.2005","article-title":"Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus","volume":"43","author":"Perkins","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0190","doi-asserted-by":"crossref","first-page":"10710","DOI":"10.1128\/JVI.00986-09","article-title":"Respiratory syncytial virus grown in Vero cells contains a truncated attachment protein that alters its infectivity and dependence on Glycosaminoglycans","volume":"83","author":"Kwilas","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0195","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fcimb.2022.858629","article-title":"Receptors for respiratory syncytial virus infection and host factors regulating the life cycle of respiratory syncytial virus","volume":"12","author":"Feng","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005318","article-title":"Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures","volume":"11","author":"Johnson","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130517","article-title":"CX3CR1 is expressed in differentiated human ciliated airway cells and co-localizes with respiratory syncytial virus on cilia in a G protein-dependent manner","volume":"10","author":"Jeong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.03.059_bb0210","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1099\/vir.0.000218","article-title":"CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells","volume":"96","author":"Chirkova","year":"2015","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0215","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41390-019-0677-0","article-title":"CX3CR1 as a respiratory syncytial virus receptor in pediatric human lung","volume":"87","author":"Anderson","year":"2020","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009469","article-title":"The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines","volume":"17","author":"King","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0225","doi-asserted-by":"crossref","first-page":"129","DOI":"10.14356\/kona.2019008","article-title":"Challenges associated with the pulmonary delivery of therapeutic dry powders for preclinical testing","volume":"36","author":"Price","year":"2019","journal-title":"KONA Powder Part. J."},{"key":"10.1016\/j.jconrel.2023.03.059_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183130","article-title":"Prerequisites for a dry powder inhaler for children with cystic fibrosis","volume":"12","author":"Lexmond","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.03.059_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaerosci.2020.105692","article-title":"High-efficiency dry powder aerosol delivery to children: review and application of new technologies","volume":"153","author":"Bass","year":"2021","journal-title":"J. Aerosol Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592300250X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592300250X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:40:52Z","timestamp":1759164052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592300250X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":47,"alternative-id":["S016836592300250X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.03.059","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of an inhalable antiviral powder formulation against respiratory syncytial virus","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.03.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}